anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Loss-of-function CHD2 (chromodomain helicase DNA-binding protein 2) mutations are associated with a spectrum of neurodevelopmental disorders often including early-onset generalized seizures, photosensitivity, and epileptic encephalopathies. Patients show psychomotor delay/intellectual disability (ID), autistic features, and behavior disorders, such as aggression and impulsivity. Most reported cases are sporadic with description of germline mosaicism only in two families. We detect the first case of parental gonosomal CHD2 mosaicism disclosed by two brothers showing mild ID, born to healthy parents. The eldest brother has a history of drug-controlled generalized tonic-clonic seizures and displays sleep disorder and aggressive behavior suggestive of Smith-Magenis syndrome (SMS). Analysis of brothers' DNAs by next-generation sequencing (NGS) custom gene panel for pediatric epilepsy and/or ID disclosed in both the same pathogenic CHD2 variant. Additional NGS experiment on genomic DNA from parents' peripheral blood and from buccal swab raised the suspicion of low-grade gonosomal mosaicism in the unaffected mother subsequently confirmed by digital polymerase chain reaction (dPCR). This report underlines as worthwhile CHD2 screening in individuals presenting ID/developmental delay, with/without epilepsy, and behavior and sleep disorders suggestive of SMS. Detecting a CHD2 variant should prime testing probands' parents by NGS coupled to dPCR on different tissues to exclude/confirm gonosomal mosaicism and define the recurrence risk.
BACKGROUND: Prior to September 2021, 55,000-90,000 hospital inpatients in England were identified as having a potentially nosocomial SARS-CoV-2 infection. This includes cases that were likely missed due to pauci- or asymptomatic infection. Further, high numbers of healthcare workers (HCWs) are thought to have been infected, and there is evidence that some of these cases may also have been nosocomially linked, with both HCW to HCW and patient to HCW transmission being reported. From the start of the SARS-CoV-2 pandemic interventions in hospitals such as testing patients on admission and universal mask wearing were introduced to stop spread within and between patient and HCW populations, the effectiveness of which are largely unknown.
MATERIALS/METHODS: Using an individual-based model of within-hospital transmission, we estimated the contribution of individual interventions (together and in combination) to the effectiveness of the overall package of interventions implemented in English hospitals during the COVID-19 pandemic. A panel of experts in infection prevention and control informed intervention choice and helped ensure the model reflected implementation in practice. Model parameters and associated uncertainty were derived using national and local data, literature review and formal elicitation of expert opinion. We simulated scenarios to explore how many nosocomial infections might have been seen in patients and HCWs if interventions had not been implemented. We simulated the time period from March-2020 to July-2022 encompassing different strains and multiple doses of vaccination.
RESULTS: Modelling results suggest that in a scenario without inpatient testing, infection prevention and control measures, and reductions in occupancy and visitors, the number of patients developing a nosocomial SARS-CoV-2 infection could have been twice as high over the course of the pandemic, and over 600,000 HCWs could have been infected in the first wave alone. Isolation of symptomatic HCWs and universal masking by HCWs were the most effective interventions for preventing infections in both patient and HCW populations. Model findings suggest that collectively the interventions introduced over the SARS-CoV-2 pandemic in England averted 400,000 (240,000 - 500,000) infections in inpatients and 410,000 (370,000 - 450,000) HCW infections.
CONCLUSIONS: Interventions to reduce the spread of nosocomial infections have varying impact, but the package of interventions implemented in England significantly reduced nosocomial transmission to both patients and HCWs over the SARS-CoV-2 pandemic.
LIPITOR may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including LIPITOR. 

###  Risk Factors for Myopathy

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher LIPITOR dosage [see Drug Interactions (7.1) and Use in Specific Populations (8.5, 8.6)]. 

###  Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

LIPITOR exposure may be increased by drug interactions due to inhibition of cytochrome P450 enzyme 3A4 (CYP3A4) and/or transporters (e.g., breast cancer resistant protein [BCRP], organic anion-transporting polypeptide [OATP1B1/OATP1B3] and P-glycoprotein [P-gp]), resulting in an increased risk of myopathy and rhabdomyolysis. Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir with LIPITOR is not recommended. LIPITOR dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2.5)]. Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir. Consider if the benefit of use of these products outweighs the increased risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)].

Concomitant intake of large quantities, more than 1.2 liters daily, of grapefruit juice is not recommended in patients taking LIPITOR [see Drug Interactions (7.1)].

Discontinue LIPITOR if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if LIPITOR is discontinued. Temporarily discontinue LIPITOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the LIPITOR dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
1. Technical Result Widening of the spectrum of preparation effect and increase in efficiency of treatment. 2. Essence A combined preparation against enteric infection comprises phage lysates of bacteria: Shigellae, Salmonellae, E.coli, Proteus, Pseudomo¬nas aeruginosa, Staphylococcus and Enterococcus and antimycotic preparation: nystatin, or Levorine, or Nizoral, or Diflukan, or Pimafucine, or Klotrimazole in therapeutically effective amount. 3. Field of Application Medicine, pharmacology.
Targeted anticancer drugs have completely changed the prognosis of malignancies during the past decades. Patients suffering from malignancies live longer and this allows adverse events of anticancer drugs to emerge, notably cardiovascular adverse events. It is particularly important because of the great morbimortality of major cardiovascular events like myocardial infarction or stroke and because of their frequency in cancer populations. Indeed, cardiovascular death is the second cause of deaths after malignancy itself in this population. Atrial fibrillation (AF) is a non rare cardiovascular adverse events associated with a shorter overall survival in some malignancies localization. The emblematic anticancer drugs promoting AF is ibrutinib belonging to the Bruton tyrosine kinase inhibitors (BTKi), which are indicated in hematological malignancies. Incidence of AF with ibrutinib is estimated to 4.92/100 person-years; 95% CI: 2.91-4.81 but is underestimated because of the absence of systematic electrocardiogram recording. The management of AF rests on anticoagulation if indicated by the CHA2DS2-VASc score, and on the choice between a rate or rhythm control strategy. Rate control is the privileged strategy because of the risk of drugs interactions of the anti-arrhythmic drugs in a context of anticancer drugs co-prescriptions. But in case of symptoms with normal heart rate, life expectancy counted in years and preserved condition, catheter ablation has to be discussed. Whereas this interventional procedure has been greatly studied in the general population, no study exists in patients with hematological malignancies. The investigators aim to describe baseline characteristics of a population of BTKi-induced AF undergone AF catheter ablation.
Sepsis-associated encephalopathy (SAE) is a significant cause of mortality in patients with sepsis. Despite extensive research, its exact cause remains unclear. Our previous research indicated a relationship between non-hepatic hyperammonemia (NHH) and SAE. This study aimed to investigate the relationship between NHH and SAE and the potential mechanisms causing cognitive impairment. In the in vivo experimental results, there were no significant abnormalities in the livers of mice with moderate cecal ligation and perforation (CLP); however, ammonia levels were elevated in the hippocampal tissue and serum. The ELISA study suggest that fecal microbiota transplantation in CLP mice can reduce ammonia levels. Reduction in ammonia levels improved cognitive dysfunction and neurological impairment in CLP mice through behavioral, neuroimaging, and molecular biology studies. Further studies have shown that ammonia enters the brain to regulate the expression of aquaporins-4 (AQP4) in astrocytes, which may be the mechanism underlying brain dysfunction in CLP mice. The results of the in vitro experiments showed that ammonia up-regulated AQP4 expression in astrocytes, resulting in astrocyte damage. The results of this study suggest that ammonia up-regulates astrocyte AQP4 expression through the gut-brain axis, which may be a potential mechanism for the occurrence of SAE.
PURPOSE: Automated scalp cooling (ASC) is available to patients undergoing chemotherapy for breast cancer to decrease chemotherapy-induced alopecia. This study sought to elucidate patient and chemotherapy nursing perspectives on the ASC experience.
METHODS: This is a survey-based study of chemotherapy nursing staff and patients with breast cancer regarding perceived efficacy, side effects, administration, support, and overall opinions of ASC. Chemotherapy nurses across a large, multi-regional tertiary healthcare system completed a one-time survey regarding their experiences in administering ASC. Breast cancer patients who utilized ASC were surveyed along with a control group who underwent alopecia-inducing chemotherapy without ASC use for comparison.
RESULTS: The majority of nursing responses reported inadequate technical support, an increased burden of administering ASC compared to other clinical duties, and that they would not recommend ASC to a family member or friend. Patients who underwent ASC reported significantly less hair loss and were significantly less likely to shave their heads or wear a wig, but this did not translate into significant differences in body image or psychosocial wellbeing responses. Time investment was the most significant burden related to ASC.
CONCLUSION: Patients using ASC reported significantly less hair loss compared to those not using ASC during alopecia-inducing breast cancer chemotherapy, but this did not translate to improved body image. The majority of chemotherapy nurses reported they lacked adequate support in administering ASC and would not recommend it. Enhanced nursing support may provide a means for improving the ASC experience for both nursing staff and patients.
Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.
Acute type A aortic dissection (ATAAD) is a life-threatening disease with high mortality. Surgery remains the gold standard for the treatment of ATAAD. In recent years, ATAAD is still a persistent challenge for cardiovascular surgeons. This is a retrospective study based on the data available in our hospital database for ATAAD patients undergoing total aortic arch replacement with elephant trunk stent under cryogenic stop circulation from January 2020 to December 2021. These patients were divided into two groups according to the surgical procedures of aortic root: continuous aortic root suture group (CARS group); "aortic root reinforcement combined with vascular grafts eversion and built-in", which was created by our group and to be named as XJ-procedure (XJ-procedure group, XJ is an acronym for Xi'an Jiaotong University). The main outcome was defined as 30-day mortality. Secondary outcomes included the postoperative bleeding necessitating re-operation and the incidence of anastomotic pseudoaneurysm, residual aortic root dissection and severe aortic regurgitation before discharge and at 3 and 6 months after the operation. This study compared baseline data, perioperative and short-term follow-up results between the two groups to evaluate the efficacy and safety of XJ-procedure in ATAAD.
Genetic samples are obtained from separate people, and at least a portion of each are purposefully combined before testing to form a pooled genetic sample. The pooled genetic sample is tested for the presence of a signature for a given known ailment. DNA identification uses discovered InDels in a region of InDel variation in a genetic sample. A pair-wise comparison is performed to reference InDels, and a distance is measured between the first InDel and the reference Indel. Reference kmers are identified in a reference genome, and in a test sample. The plurality of sample kmers are filtered to those which have a 1 edit distance from a corresponding one of the plurality of reference kmers. Reads that have kmers that do not have a 1 edit distance from the corresponding one of the plurality of reference kmers are identified, and multiple single-mutations are eliminated from candidate InDel reads.
Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.
PROBLEM TO BE SOLVED: To obtain a safe cosmetic derived from natural plants, free from adverse effect and excellent in beautifying and whitening action having antityrosinase active action and moisture-retaining action. SOLUTION: This cosmetic comprises a squeezed material and/or an extract from a plant belonging to the genus Calanthe as an active ingredient. In the squeezed material and extract from calantheous plant, e.g. its alcohol extract has dose-dependently antityrosinase active action. Consequently, the cosmetic can efficiently suppress production of melanin pigment (black brown) based on tyrosinase active enzyme of tyrosine which is a kind of protein-constituting amino acid which is present in skin and has excellent beautifying and whitening effect. The cosmetic is excellent also in moisture retaining effect. Therefore, the cosmetic can widely be used for beautifying and whitening agent, cream, soap, etc., and can safely be used, because action irritating skin is not be recognized.
Obesity is a frequent disease mainly caused by environmental/polygenic factors and more rarely caused by the alteration of a single gene ("monogenic obesity"). The diagnosis of these rare forms can lead to personalized management (new treatments, prognosis, adapted hygienic and dietary rules) and family screening. The genetic analysis of monogenic obesity classically includes the five best known genes of the leptin-melanocortin pathway: LEP, LEPR, POMC, PCSK1 and MC4R. The limitation to these five genes allows the diagnosis of only 1 to 3% of monogenic obesity. The use of a genetic panel covering more known causes of monogenic obesity on a pediatric cohort of severe and early obesity will allow to evaluate the relevance of enlarged analyses to adapt the management of these rare diseases. In addition, the penetrance and mode of transmission of some genes related to monogenic obesity remain to be precised.

The study aims to analyze the sequencing of 71 genes related to monogenic obesity in a cohort of 100 patients with early (\<6 years) and severe obesity. The clinical and biological phenotype of each case will be documented by retrospective medical datas. Concurrent analysis of a cohort of 100 patients with normal BMI (" control ") aims to better define the genes and transmission patterns with significant penetrance in obesity.

The study will include a first part aiming at including patients and controls in the study for which the Biochemistry laboratory of the Bordeaux University Hospital already has a DNA sample (maximum duration 24 months). The patient cohort will be composed of cases that have already benefited from the genetic analysis of the panel of 71 genes as part of their care. The control cohort will be sequenced for the study. The list of 71 genes comes from the recommendations of the French National Plan of Care regarding obesity of rare causes, adding the genes involved in Bardet Biedl Syndrome. The second step of the work will be to collect the clinical, biological and genetic datas of the patient and control cohorts. The third step will be the datas analyse.
A multiple emulsion has polar phase A1, non polar phase B, and polar phase A2, or non polar phase B1, polar phase A, and non polar phase B2. The emulsion further comprises a coalescence stability amount of particulate solid having mean particle size smaller than 1 microm.  A multiple emulsion has polar phase A1, non polar phase B, and polar phase A2, or non polar phase B1, polar phase A, and non polar phase B2. The emulsion further comprises a coalescence stability amount of particulate solid having mean particle size smaller than 1 microm. It is provided that surface-active substances are present only up to maximum concentration less than 0.1 times critical micelle concentration of the substances in phases A, A1, A2. Independent claims are also included for: (1) a method of producing (A1/B/A2) multiple emulsion comprising dispersing particulate solids in B phase to form a dispersion, dispersing this dispersion in A1 phase to form an emulsion, and dispersing the emulsion in A2 phase containing particulate solids; (2) a method of producing (B1/A/B2) multiple emulsion comprising dispersing particulate solids in B1 phase to form a dispersion, dispersing this dispersion in A phase to form an emulsion, and dispersing the emulsion in B2 phase containing particulate solids; and (3) a process for controlled release of active ingredients into surrounding area comprising incorporating the active ingredient into dispersed A1/B phase of A1/B/A2 multiple emulsion, or into a dispersed B1/A phase of B1/A/B2 emulsion.
PURPOSE: To obtain composite particles excellent in economy which are prepared by coating the surfaces of powder particles used as a cosmetic powder directly with boron nitride powder, thus improved in unnatural glaring and finish while the merits of the boron nitride powder, namely spreadability, gloss, adhesion and the like is usefully maintained. CONSTITUTION: The mother particle of cosmetic powder such as nylon, mica, talc or the like is directly coated with boron nitride powder on its surface to give this composite particle. The amount of the coating boron nitride powder is 5-70wt.% based on the mother particle. The average particle size of the mother particle is pref. 1-50μm, and that of the boron nitride powder is 0.005-5μm. Especially, the composite particle of less than 0.5 regular reflectance is preferred. This composite particle is produced by allowing the boron nitride powder to adhere to the surface of organic particle statically, then strengthening the bond between them forcibly with a physical force. Or, a suspension containing an inorganic particle, boron nitride powder and a dispersant is spray- dried and calcined. The composite particles are added to a cosmetic in an amount of 1-80wt.%.
The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular, the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B. Accordingly, a method of screening for inhibitors of the biological activity of VEGF-B is also provided.
PROBLEM TO BE SOLVED: To obtain a composition containing two kinds of specific compounds, exhibiting a safe and synergistic active carbon-suppressing action and extremely useful for health and beauty, and to obtain a hypotensive medicine. SOLUTION: This active oxygen-suppressing composition contains at least one kind of compound selected from phytic acid and phytic acid salts and a green tea extract and/or vitamin C. The green tea extract is preferably added in an amount of 15-800 pts.wt. (converted into evaporation residues) per 100 pts.wt. of the phytic acid or its salts. The vitamin C is similarly added in an amount of 15-800 pts.wt. The composition is preferably used in an aqueous solution. The aqueous solution composition is excellent in absorption effects into bodies, and enables to widen its application field as aqueous beverages and foods. The composition gives an excellent hypotensive effect caused by the active oxygen-suppressing action.  The composition exhibits effects on the therapy, amelioration, etc., of diseases caused by blood flow disorders, geriatric diseases, internal diseases, beauty, dermatitis, etc.